Bristol Myers Squibb Company (NYSE:BMY) Position Boosted by Achmea Investment Management B.V.

Achmea Investment Management B.V. raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 180.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 665,947 shares of the biopharmaceutical company's stock after acquiring an additional 428,888 shares during the period. Achmea Investment Management B.V.'s holdings in Bristol Myers Squibb were worth $40,617,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. LaFleur & Godfrey LLC boosted its holdings in Bristol Myers Squibb by 3.5% during the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after buying an additional 1,487 shares in the last quarter. Brighton Jones LLC boosted its holdings in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after buying an additional 4,935 shares during the period. Bank Pictet & Cie Europe AG purchased a new position in shares of Bristol Myers Squibb in the fourth quarter worth approximately $13,094,000. Lake Street Advisors Group LLC raised its holdings in shares of Bristol Myers Squibb by 20.4% during the fourth quarter. Lake Street Advisors Group LLC now owns 14,722 shares of the biopharmaceutical company's stock valued at $833,000 after acquiring an additional 2,498 shares during the period. Finally, Advisor OS LLC raised its stake in Bristol Myers Squibb by 30.2% during the 4th quarter. Advisor OS LLC now owns 5,457 shares of the biopharmaceutical company's stock valued at $309,000 after purchasing an additional 1,267 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Up 0.0%

BMY stock opened at $46.68 on Friday. Bristol Myers Squibb Company has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a market cap of $95.01 billion, a PE ratio of 17.48, a price-to-earnings-growth ratio of 1.38 and a beta of 0.38. The business's 50-day simple moving average is $47.96 and its 200 day simple moving average is $54.02. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The company had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the previous year, the business earned ($4.40) earnings per share. The company's quarterly revenue was down 5.6% on a year-over-year basis. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.31%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 92.88%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of research analyst reports. Jefferies Financial Group lowered their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $58.00.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.